-
11.发明申请TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING NANODROPLETS FOR THE TREATMENT PSORIASIS 有权含有NANODROPLETS用于治疗PSORIASIS的局部药物组合物公开(公告)号：US20130273172A1
公开(公告)日：2013-10-17
申请号：US13880519
申请日：2011-10-18
申请人： Sunilendu Bhushan Roy , Jay Shantilal Kothari , Shafiq Sheikh , Jitendra Dasharathlal Patel , Jinesh Suresh Pancholi
发明人： Sunilendu Bhushan Roy , Jay Shantilal Kothari , Shafiq Sheikh , Jitendra Dasharathlal Patel , Jinesh Suresh Pancholi
IPC分类号： A61K9/107 , A61K31/573 , A61K31/60
CPC分类号： A61K9/107 , A61K9/0014 , A61K9/1075 , A61K31/573 , A61K31/60 , A61K47/44 , B82Y5/00 , A61K2300/00
摘要： The present invention relates to stable topical pharmaceutical compositions for the treatment of psoriasis. Disclosed are in particular nonoemulsions comprising nano size droplets of one or more anti-psoriasis agents, e.g. clobetasol and/or salicylic acid. These compositions exhibit greater permeability, and improved bioavailability. The invention also relates to processes for the preparation of such compositions.
摘要翻译： 本发明涉及用于治疗牛皮癣的稳定的局部药物组合物。 公开了特别是包含一种或多种抗牛皮癣药剂的纳米尺寸液滴的非乳液，例如。 氯倍他索和/或水杨酸。 这些组合物表现出更大的渗透性和改善的生物利用度。 本发明还涉及制备这种组合物的方法。
-
公开(公告)号：US20150064254A1
公开(公告)日：2015-03-05
申请号：US14234847
申请日：2012-01-05
IPC分类号： A61K9/107 , A61K9/00 , A61K31/196
CPC分类号： A61K9/1075 , A61K9/0014 , A61K31/196
摘要： The present invention relates to a method for the treatment of pain and inflammation. In particular, the present invention relates to a method for the treatment of musculo-skeletal and connective tissue pain/inflammations. Further, the invention relates to reducing the incidence and seventy of adverse events resulting from administration of diclofenac. The method comprises administration of a topical pharmaceutical composition of diclofenac or its salts.
摘要翻译： 本发明涉及治疗疼痛和炎症的方法。 特别地，本发明涉及一种治疗肌肉骨骼和结缔组织疼痛/炎症的方法。 此外，本发明涉及减少由施用双氯芬酸引起的不良事件的发生率和七十次。 该方法包括施用双氯芬酸或其盐的局部药物组合物。
-
公开(公告)号：US09713590B2
公开(公告)日：2017-07-25
申请号：US14234847
申请日：2012-01-05
IPC分类号： A61K9/107 , A61K31/196 , A61K9/00
CPC分类号： A61K9/1075 , A61K9/0014 , A61K31/196
摘要： The present invention relates to a method for the treatment of pain and inflammation. In particular, the present invention relates to a method for the treatment of musculo-skeletal and connective tissue pain/inflammations. Further, the invention relates to reducing the incidence and seventy of adverse events resulting from administration of diclofenac. The method comprises administration of a topical pharmaceutical composition of diclofenac or its salts.
-
公开(公告)号：US20100145053A1
公开(公告)日：2010-06-10
申请号：US12295932
申请日：2007-04-03
IPC分类号： C07D495/04
CPC分类号： A61K31/4365 , A61K9/2027 , A61K9/2031 , A61K9/2054
摘要： A once daily dosage form comprising Clopidogrel or a salt of Clopidogrel equivalent to 50 mg to 150 mg Clopidogrel is disclosed. Said dosage form provides at least one of the following in vivo plasma profile of Clopidogrel selected from: (a) Mean Tmax of about 3 or more hours. (b) Mean Cmax not above 1000 picogram/ml. (c) Mean AUC0-49h of more than 2500 picogram/ml/hr.
摘要翻译： 公开了包含氯吡格雷或氯吡格雷盐等于50mg至150mg氯吡格雷的每日一次剂型。 所述剂型提供氯吡格雷的以下体内血浆曲线中的至少一种，其选自：（a）约3小时以上的平均T max。 （b）平均Cmax不高于1000皮克/毫升。 （c）平均AUC 0-49h超过2500皮克/毫升/小时。
-
公开(公告)号：US20120093882A1
公开(公告)日：2012-04-19
申请号：US13262987
申请日：2010-03-22
IPC分类号： A61K9/107 , A61K31/196 , A61P29/00 , C07C229/42 , A61P25/00 , B82Y40/00 , B82Y5/00
CPC分类号： A61K9/0014 , A61K9/1075 , A61K31/196
摘要： The present invention discloses a stable pharmaceutical composition of diclofenac or salts thereof comprising nano size droplets of diclofenac or salts thereof, wherein the composition exhibits a significant difference in one or both of the rate and extent of absorption of diclofenac or salts thereof as compared to formulation of diclofenac marketed under the trade name Voveran®
摘要翻译： 本发明公开了一种双氯芬酸或其盐的稳定的药物组合物或其盐，其包含双氯芬酸或其盐的纳米尺寸液滴，其中与制剂相比，组合物在双氯芬酸或其盐的吸收速率和吸收程度中的一个或两个方面显示出显着差异 的双氯芬酸以商品名Voveran®销售
-
公开(公告)号：US07115281B2
公开(公告)日：2006-10-03
申请号：US10616240
申请日：2003-07-08
申请人： Romi Barat Singh , Pannanchukunnath Manoj Kumar , Vishnubhotla Nagaprasad , Sunilendu Bhushan Roy , Rajiv Malik
发明人： Romi Barat Singh , Pannanchukunnath Manoj Kumar , Vishnubhotla Nagaprasad , Sunilendu Bhushan Roy , Rajiv Malik
CPC分类号： A61K9/2059 , A61K9/14 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K31/165
摘要： The invention relates to processes for preparing, and pharmaceutical compositions of, modafinil dosage forms for oral administration. The dosage forms include a mixture of coarse and fine particles of modafinil. The process for preparing modafinil oral dosage forms includes forming a dosage form that includes about 7%–25% by weight of modafinil particles having diameters greater than 220 μm and about 75%–93% by weight of modafinil particles having diameters less than 220 μm.
摘要翻译： 本发明涉及用于口服给药的莫达非尼剂型的制备方法和药物组合物。 剂型包括莫达非尼的粗颗粒和细颗粒的混合物。 莫替非尼口服剂型的制备方法包括形成剂型，其包含约7％-25％重量的直径大于220μmm和约75％-93％的直径小于220μmm的莫达非尼颗粒的莫达非尼颗粒 。
-
公开(公告)号：US06740337B2
公开(公告)日：2004-05-25
申请号：US09829246
申请日：2001-04-09
IPC分类号： A61K914
CPC分类号： A61K9/14 , A61K9/4858 , A61K31/07
摘要： The present invention relates to a bioavailable pharmaceutical composition of 13-cis vitamin A acid (also known as 13-cis retinoic acid and isotretinoin) and a process for preparing the same. 13-cis vitamin A acid is a relatively water insoluble compound that degrades when exposed to light and atmospheric oxygen. Due to its instability and relative insolubility, the bioavailability of the drug after oral administration is difficult to achieve and has always been a challenge to a development pharmacist. It would therefore be desirable to provide a dosage form in which the drug is stable and predictably bioavailable.
摘要翻译： 本发明涉及13-顺式维生素A酸（也称为13-顺式视黄酸和异维A酸）的生物可利用药物组合物及其制备方法。 13-顺式维生素A酸是一种相对不溶于水的化合物，当暴露于光和大气中时会降解。 由于其不稳定性和相对不溶性，口服给药后药物的生物利用度难以实现，并且一直是开发药剂师的挑战。 因此，期望提供其中药物是稳定的并且可预测地具有生物利用度的剂型。
-
18.发明申请DELAYED RELEASE ORAL DISINTEGRATING PHARMACEUTICAL COMPOSITIONS OF LANSOPRAZOLE 审中-公开延迟释放口服兰索唑药物组合物公开(公告)号：US20130202688A1
公开(公告)日：2013-08-08
申请号：US13695646
申请日：2011-05-03
IPC分类号： A61K9/14
CPC分类号： A61K9/14 , A61K9/0056 , A61K9/2081 , A61K9/5026 , A61K9/5078 , A61K31/4439
摘要： The present invention relates to delayed release oral disintegrating pharmaceutical compositions of lansoprazole or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions.
摘要翻译： 本发明涉及兰索拉唑缓释口服崩解药物组合物或其药学上可接受的盐。 本发明还涉及制备这种组合物的方法。
-
公开(公告)号：US20100239661A1
公开(公告)日：2010-09-23
申请号：US12446842
申请日：2007-10-23
IPC分类号： A61K9/48 , A61K9/14 , A61K31/575 , A61K9/20 , A61P1/00
CPC分类号： A61K31/575 , A61K9/14 , A61K9/2054 , A61K9/4866
摘要： A pharmaceutical composition is disclosed. The composition comprises a therapeutically effective amount of active pharmaceutical ingredient that is Ursodiol or its pharmaceutically acceptable salts thereof with one or more pharmaceutically acceptable excipients, wherein said active pharmaceutical ingredient present in the form of micronized and unmicronized particles in the ratio about 5:95 to about 95:5.
摘要翻译： 公开了药物组合物。 该组合物包含治疗有效量的活性药物成分，其是与一种或多种药学上可接受的赋形剂的二硫醇或其药学上可接受的盐，其中所述活性药物成分以微粉化和非微粒化的形式存在，比例为约5:95至 约95：5。
-
公开(公告)号：US09101541B2
公开(公告)日：2015-08-11
申请号：US13643386
申请日：2011-04-25
申请人： Sunilendu Bhushan Roy , Sushrut Krishnaji Kulkarni , Kiritkumar Maulik Panchal , Shubhashchandra Shailendra Mandge
发明人： Sunilendu Bhushan Roy , Sushrut Krishnaji Kulkarni , Kiritkumar Maulik Panchal , Shubhashchandra Shailendra Mandge
IPC分类号： A61K9/14 , A61K9/16 , A61K9/28 , A61K31/436 , A61K9/20
CPC分类号： A61K9/145 , A61K9/1623 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2866 , A61K31/436
摘要： The present invention discloses a stable solid pharmaceutical matrix composition comprising sirolimus or pharmaceutically acceptable salts thereof along with one or more sugars.
摘要翻译： 本发明公开了一种稳定的固体药物基质组合物，其包含西罗莫司或其药学上可接受的盐以及一种或多种糖。
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.025 秒)
